MANAGEMENT TEAM

Having graduated from the Keio University School of Medicine, he engaged in clinical work at the Japanese Red Cross Society Medical Center, and was involved in the medical treatment of many patients as a respiratory physician. In 2012, he went off to study abroad at overseas graduate schools gaining global experience in China and the United States. After graduating from a US graduate school with a Major in public health, he has been engaged in medical informatics research. After returning home to Japan, he founded CureApp Inc. in 2014. Even now, he continues his clinical practice once a week and remains in the medical scene.

He completed his Masters of Business Administration (MBA) from the China Europe International Business School (CEIBS) as well as a Masters of Public Health from the John Hopkins University School of Public Health (MPH) in the United States.

Having Graduated from Kyoto University Law School and passing the (former) state law examination, he participated in domestic VC, worked as a Bain & Company strategic consultant and then engaged in numerous projects centered around medicine and healthcare. He acquired a wide range of findings in the industry from structure to value in the area of pharmaceuticals from medical R&D to marketing and sales.

From 2012 to 2013 he studied abroad (taking a leave of absence) at the China Europe International Business School (CEIBS). From there he began to see the potential of Satake's business vision that was synchronous to his own ideas and started working with the CureApp team in October of 2016.

Graduated from the Graduate School of Human Informatics, Department of Material and Life science, Nagoya University. After holding key positions in marketing, sales, and business strategy in the pharmaceutical industry for over 20 years, he has been engaged in business management as an executive officer and head of business division at several global pharmaceutical companies since 2018. He has worked as the lecturer in marketing and management strategy at the Graduate School of Management.
He has been in current role since July 2023.

Following his leadership in clinical development at two pharmaceutical companies, he joined CureApp in October 2019. Serving as Head of Clinical Development and Business Lead for hypertension, he led the launch of CureApp HT, a prescription digital therapeutic app. After directing clinical development and regulatory affairs, he assumed leadership of the Medical Division in February 2023. He spearheads digital therapeutic programs from clinical trials to regulatory approval and reimbursement, establishing a robust medical framework to accelerate business growth through technology and evidence generation.

After leading UI/UX design at a design consulting firm and Samsung Electronics Japan, he completed the master's program in design and management at the Massachusetts Institute of Technology (MIT) as a Fulbright Scholar. During his studies, he played a key design role in launching multiple startups, and upon returning to Japan, co-founded a healthcare startup, serving as CPO and COO. He joined CureApp in May 2023, where he oversees product management and design organizations, driving the maximization of product value through the dual engines of product development and go-to-market.

After completing a master's program in physics at the University of Tokyo, he led app renewals and new application launches at Yahoo Japan. Subsequently, he was a founding member of a VR startup, scaled the engineering organization at GLOBIS from 3 to 70 members, and served as Vice President at a software development company. In August 2022, he joined CureApp as VPoE, driving engineering transformation and building a generative AI-native organization. He is also active as a Google Developer Expert, evangelizing tech and presenting at industry conferences in Japan and internationally.

As a Certified Public Accountant (CPA), he led statutory audits and M&A advisory over a decade at PwC, and directed investment banking operations at the Development Bank of Japan, including large-scale transactions exceeding 100 billion yen. At a marketing SaaS startup, he orchestrated major overseas fundraising and spearheaded IPO preparations. In September 2022, he joined CureApp, where he directs corporate planning and establishes a robust management and governance framework through FP&A, financing, and internal controls/J-SOX compliance.

After driving HR system redesign, organizational culture transformation, and talent development at Sumitomo Pharma and Fuji Oil, he joined CureApp in November 2022. As an HRBP, he stabilized organizational foundations and renewed HR systems. As Head of Human Resources since April 2024, he directs company-wide HR strategy, employee engagement, and culture development, maximizing organizational capabilities to accelerate business growth. He holds a Master of Business Administration (MBA).

Having completed his degree from the Department of Chemical Engineering at the Tokyo Institute of Technology Graduate School in Science and Engineering he has been engaged in the investment and support of university-originated ventures and ideas from the start-up stage since 2008. As a person in charge of an industry-academia collaborative investment group at JAFCO Co., Ltd., his major investment destinations include CYBERDYNE, Spiber, Microwave Chemistry, and more. He established Beyond Next Ventures Co., Ltd. in August 2014 and is currently operating a fund specializing in seed and early stage investments in university-launched and deep tech startups.

Mr. Saito received his M.B.A. from INSEAD, LL.M. in corporate law from New York University and LL.B. from the University of Tokyo. He is a Director advising Carlyle's funds on buyout opportunities in Japan, with focus on healthcare and consumer sectors. He is based in Tokyo. Since joining Carlyle in 2006, He has advised on seven investments including CureApp, Inc., Solasto Corp. (formerly N.I.C.Corp), Oyatsu Company, Ltd., and Orion Breweries, Ltd. Prior to joining Carlyle, He spent five years at Nishimura & Partners, one of the Big Four law firms in Japan, covering various aspects of corporate activities including M&A transactions. He is admitted to practice law in Japan and New York State. He serves on the Board of Directors of Orion Breweries, Ltd. May 2022 serves on the Board of Directors of CureApp, Inc.

Certified Public Accountant and Certificated Public Tax Accountant. Representative of the Kadota Accounting Office.
After passing the former second stage of the Certified Public Accountant（CPA） examination in 2001, she joined Deloitte Touche Tohmatsu (currently Deloitte Touche Tohmatsu LLC), where she was involved in accounting audits and advisory services.
In 2014, she established theKadota Accounting Office. She has served as an outside audit & supervisory board member for multiple venture companies. In September 2024, she was appointed as the full-time outside audit & supervisory board member of CureApp, Inc.

1999 Graduated from Keio Senior High School.
2002 Passed the Certified Public Accountant 2nd Exam, and registered as an assistant certified public accountant.
2003 Graduated from the Faculty of Business and Commerce, Keio University.
2003- Engaged in accountancy and public offering support services at ChuoAoyama Audit Corporation.
2006 Passed the Certified Public Accountant 3rd Exam, and registered as a certified public accountant.
2006- Engaged in a broad range of services, including M&A advisory services at the Advisory Division of PwC.
2011 Engaged in internal advisory services (sales support services) and financial affairs at M&A Group, Structured Finance Office, Finance Department of a major general trading company.
2013 Engaged in a number of domestic and international cases at the Advisory Division of PwC.
2014 Assumed the positions of Director of Yamaguchi Certified Public/Tax Accountant Office and Representative Director of CPA Partners Co., Ltd.
2015 Assumed the position of representative partner of Tax Partners, Co., Ltd.
May 2015 Assumed the position of part-time auditor of CureApp, Inc.

Partner (Attorney-at-law) at Sonderhoff & Einsel, Law and Patent Office. Passed the bar exam in Japan in 2005 and graduated from the University of Tokyo (LL.B.) in 2006. Graduated from Georgetown University Law Center (LL.M.) and passed the New York state bar examination in 2013. Engaged in M&A and corporate support services at Clifford Chance Law Office (2007 – 2011) and K&L Gates Gaikokuho Joint Enterprise (2011 – 2017) and moved to Sonderhoff & Einsel in 2017. She focuses on healthcare legal and corporate matters and works also as an advisor of the International Affairs Working Group of Japan Pharmaceutical Industry Legal Affairs Association and Clinical Trial Working Group of Japan Pharmaceutical Industry Legal Affairs Association, a supporter of Medical Innovation Support Office of Ministry of Health, Labour and Welfare (MEDISO), a member of Ethical Review Board (since July 2019) and steering committee of the Council for Industrial use of Biological and Environmental Repositories (CIBER).
September 2020 Assumed the position of part-time auditor of CureApp, Inc.